Docetaxel combination produces 2-year survival advantage in NSCLC patients
- PMID: 11780700
Docetaxel combination produces 2-year survival advantage in NSCLC patients
Similar articles
-
Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.Prescrire Int. 2005 Feb;14(75):16-8. Prescrire Int. 2005. PMID: 15751170
-
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):46-9. Oncology (Williston Park). 1997. PMID: 9364543 Review.
-
Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):42-5. Oncology (Williston Park). 1997. PMID: 9364542 Review.
-
Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.Semin Oncol. 1997 Aug;24(4 Suppl 14):S14-5-S14-8. Semin Oncol. 1997. PMID: 9335516
-
Docetaxel in the management of advanced non-small cell lung cancer.Semin Oncol. 1998 Jun;25(3 Suppl 8):15-9. Semin Oncol. 1998. PMID: 9704671 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical